Compound ID | 1504
Class: Nitroimidazole
Spectrum of activity: | Gram-positive |
Details of activity: | Effective against C. difficile and Fusobacterium infections. Only effective against anaerobic bacteria. |
Institute where first reported: | Pfizer, USA |
Year first mentioned: | 1960 |
Highest developmental phase: | Approved by FDA in 1995 |
Development status: | Approved |
Reason Dropped: | Other formulations were discontinued |
Chemical structure(s): | |
Canonical SMILES: | CC1=NC=C(N1CCO)[N+](=O)[O-] |
Isomeric SMILES: | CC1=NC=C(N1CCO)[N+](=O)[O-] |
InChI: | InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3 |
InChI Key: | VAOCPAMSLUNLGC-UHFFFAOYSA-N |
Structure link: | https://pubchem.ncbi.nlm.nih.gov/compound/4173 |
External links: | |
Guide to Pharmacology: | metronidazole |
Main Source: | https://academic.oup.com/cid/article/50/Supplement_1/S16/365006 |
Citation: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC89320/ |